Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05858632 · ClinicalTrials.gov registry record · Phase 4
Immune Spatial Features of Guselkumab Cutaneous Response
A Phase 4 study of Psoriasis of Scalp, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT05858632: Recruiting Phase 4 study of Psoriasis of Scalp, sponsored by University of California, San Francisco.
NCT05858632 is a Phase 4 study of Psoriasis of Scalp that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 10 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05858632, a Phase 4 study of Psoriasis of Scalp, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This study examines the effect of IL-23 blockade with Guselkumab on the immune cells of scalp psoriasis lesions.
Primary Outcome
PSSI measures the extent of psoriasis involvement and the severity of erythema, infiltration, and desquamation of the scalp. PSSI scores will be taken pre- and mid-treatment. Scores range from 0 to 72, with higher scores indicating more severity.
Conditions Studied
Interventions
- DRUG Guselkumab
Study Locations (1)
California
- University of California San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2023-07-01 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 4 |
What NCT05858632 shows while recruiting
NCT05858632 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Psoriasis of Scalp appearing as the primary indexed condition, and to 1 intervention - of which Guselkumab is the first listed.
NCT05858632 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05858632 about?
NCT05858632 is a clinical study titled "Immune Spatial Features of Guselkumab Cutaneous Response". This study examines the effect of IL-23 blockade with Guselkumab on the immune cells of scalp psoriasis lesions.
What is the current status of trial NCT05858632?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2023-07-01. Estimated completion is 2026-06-30.
What conditions does trial NCT05858632 study?
This clinical trial studies the following conditions: Psoriasis of Scalp.
What interventions are being tested in trial NCT05858632?
The interventions under investigation include: Guselkumab (DRUG).
Who is sponsoring clinical trial NCT05858632?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05858632 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05858632's enrollment target sits among peer trials
10 1941st of 2000 higher than 33 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI